Stereotactic Body Radiotherapy for Oligometastatic Disease

G. G. Hanna, D. Landau

Research output: Contribution to journalLiterature reviewpeer-review

25 Citations (Scopus)


Stereotactic body radiotherapy (SBRT) is now an established therapy in stage I lung cancer with comparable local control rates to surgical resection. Owing to the conformity of treatment dose delivery and with appropriate fractionation considerations, minimal side-effects to surrounding normal tissues are observed in most patients. SBRT is now being used in the treatment of oligometastatic disease, alone or alongside systemic therapy. At present there is a paucity of evidence available showing a clinical benefit, but several international studies are being set-up or have started recruitment. This overview considers the clinical entity of an oligometastatic state, discusses the role of SBRT in the management of oligometastatic disease and discusses potential novel therapy combinations with SBRT.
Original languageEnglish
Pages (from-to)290-97
Number of pages8
JournalClinical Oncology
Issue number5
Early online date12 Mar 2015
Publication statusPublished - May 2015


  • Stereotactic
  • Radiotherapy
  • Oligometastatic


Dive into the research topics of 'Stereotactic Body Radiotherapy for Oligometastatic Disease'. Together they form a unique fingerprint.

Cite this